PreveCeutical Medical Inc. (the ?Company?or ?PreveCeutical?) (CSE: PREV, OTCQB: PRVCF, FSE: 18H), announces the arrival of the first shipment of ?dried cannabis flower and oils from Aurora Cannabis Inc. (TSX: ACB) (OTCQB: ACBFF) at the Pharmacy Australia Centre of Excellence (?PACE?), University of Queensland (?UQ?).
Testing of the imported cannabis strains in the application of soluble gel (?Sol-gel?) drug delivery technology to cannabinoids (see news release dated April 24, 2017) is now expected to commence.? The purpose of the testing will be to develop therapies for relief from a range of symptoms, including pain, inflammation, seizures and neurological disorders.? The Sol-gel drug delivery research program will be led by UQ Researcher and PreveCeutical?s Chief Research Officer, Dr.?Harendra Parekh.
The Sol-gel program aims to develop a system that will increase the bioavailability of drugs by using a nose-to-brain delivery system. ?The advantages of Sol-gels over conventional liquid nasal sprays include sustained delivery and therapeutic effects, reduced dosage requirements, and reduced irritation and other negative side effects.
PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products.
PreveCeutical aims to be a leader in preventive health sciences and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; the Sol-gel Program; Nature Identical? peptides for treatment of various ailments; non-addictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury).